Fesarius Therapeutics

Executive Summary

Fesarius Therapeutics is a preclinical-stage biotechnology company developing advanced tissue engineering solutions for dermal regeneration. Founded in 2021 and based in Cambridge, Massachusetts, the company's lead candidate, DermiSphere™ hDRT, is a novel hydrogel-based dermal regeneration template designed to treat full-thickness skin loss. The product aims to address significant unmet needs in wound healing, particularly for burn victims and patients with chronic wounds, by providing a scaffold that promotes native tissue regeneration. Fesarius leverages proprietary biomaterial technology to enhance patient quality of life and reduce healthcare costs associated with complex wound care. As a private company in the early-stage biotech landscape, Fesarius is focused on advancing its preclinical studies to enable regulatory filings and eventual clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical efficacy studies in large animal models60% success
• Q1 2027Series A financing round to fund IND-enabling studies50% success
• Q3 2027First-in-human clinical trial initiation (Phase I)30% success